دورية أكاديمية
The lupus anticoagulant titer is associated with elevated antiphosphatidylserine/prothrombin immunoglobulin-M isotype antibody levels.
| العنوان: | The lupus anticoagulant titer is associated with elevated antiphosphatidylserine/prothrombin immunoglobulin-M isotype antibody levels. |
|---|---|
| المؤلفون: | Saadalla A; Department of Pathology, University of Utah, Salt Lake City, Utah, USA.; ARUP Laboratories, Salt Lake City, Utah, USA., Chen D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Stuart M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Pruthi R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Heikal N; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Snyder M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Ashrani A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Seheult J; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. |
| المصدر: | International journal of laboratory hematology [Int J Lab Hematol] 2024 Aug; Vol. 46 (4), pp. 695-704. Date of Electronic Publication: 2024 Feb 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-553X (Electronic) Linking ISSN: 17515521 NLM ISO Abbreviation: Int J Lab Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Blackwell Scientific Publications, c2007- |
| مواضيع طبية MeSH: | Lupus Coagulation Inhibitor*/blood , Prothrombin*/immunology , Immunoglobulin M*/blood , Phosphatidylserines*/immunology, Humans ; Female ; Male ; Cross-Sectional Studies ; Middle Aged ; Adult ; Aged ; Partial Thromboplastin Time ; Immunoglobulin Isotypes/blood |
| مستخلص: | Background: Clot based assays used for lupus anticoagulant (LAC) detection are typically interpreted in a qualitative fashion and may not reflect LAC potency. In this cross-sectional study, we describe a method for quantifying the LAC titer using serial (dependent) two-fold dilutions in normal pooled plasma. Methods: Serial dilutions of 51 residual plasma samples from 50 patients were tested using the Russell's viper venom screening time (DRVVT) and activated partial thromboplastin screening time (APTT) methodologies. The measured clotting times and the corresponding dilution factors were then used to derive a four-parameter logistic model. The LAC titer for each patient was interpolated as the sample dilution that corresponds to the upper reference interval limit of the corresponding assay. Results: Calculated APTT and DRVVT LAC titers displayed a strong linear correlation (R 2 = 0.84) between each other, but not with the degree of prolongation of the APTT/DRVVT screening time in the neat undiluted samples. Using data driven partitioning, patients could be grouped into low (<10) or high (≥10) DRVVT LAC titer. There were no significant differences in anticardiolipin (aCL) or anti-beta 2 glycoprotein 1 (aB2GPI) antibody levels or prevalence of thromboembolic events between low and high LAC titer groups. In contrast, antiphosphatidylserine/prothrombin (aPS/PT) IgM antibody levels, but not IgG, were significantly higher in the high LAC titer group. Conclusions: The degree of prolongation of the APTT/DRVVT screening time is not correlated with the LAC titer. Only aPS/PT IgM antibodies levels were strongly correlated with the LAC titers. Additional studies are warranted to determine clinical implications of high LAC titers. (© 2024 John Wiley & Sons Ltd.) |
| References: | Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;379(13):1290. doi:10.1056/NEJMc1808253. Svenungsson E, Antovic A. The antiphospholipid syndrome—often overlooked cause of vascular occlusions? J Intern Med. 2020;287(4):349‐372. doi:10.1111/joim.13022. Barbhaiya M, Zuily S, Naden R, et al. ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75:1687‐1702. doi:10.1002/art.42624. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295‐306. doi:10.1111/j.1538‐7836.2006.01753.x. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737‐1740. doi:10.1111/j.1538‐7836.2009.03555.x. Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828‐2839. doi:10.1111/jth.15047. Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of “non‐criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105(3):562‐572. doi:10.3324/haematol.2019.221945. Zohoury N, Bertolaccini ML, Rodriguez‐Garcia JL, et al. Closing the serological gap in the antiphospholipid syndrome: the value of “non‐criteria” antiphospholipid antibodies. J Rheumatol. 2017;44(11):1597‐1602. doi:10.3899/jrheum.170044. Zhang S, Zhang F, Li Y. Should aPS/PT be incorporated into the routine serological tests in the diagnosis of antiphospholipid syndrome? J Rheumatol. 2019;46(1):114‐116. doi:10.3899/jrheum.171402. Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010;115(4):870‐878. doi:10.1182/blood‐2009‐09‐244426. Schjetlein R, Sletnes KE, Wisløff F. A quantitative, semi‐automated and computer‐assisted test for lupus anticoagulant. Thromb Res. 1993;69(2):239‐250. doi:10.1016/0049‐3848(93)90049‐t. H21‐A5 C. Transport, and Processing of Blood Specimens for Testing Plasma‐Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline. 5th ed. Clinical and Laboratory Standards Institute; 2008. Clyne LP, White PF. Time dependency of lupuslike anticoagulants. Arch Intern Med. 1988;148(5):1060‐1063. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827‐1832. doi:10.1182/blood‐2002‐02‐0441. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus. 2014;23(14):1468‐1476. doi:10.1177/0961203314545410. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high‐risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714‐4718. doi:10.1182/blood‐2011‐03‐340232. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost. 2006;96(3):337‐341. doi:10.1160/TH06‐05‐0287. Egri N, Bentow C, Rubio L, et al. Anti‐phosphatidylserine/prothrombin antibodies at two points: correlation with lupus anticoagulant and thrombotic risk. Front Immunol. 2021;12:754469. doi:10.3389/fimmu.2021.754469. Zhu R, Cheng CY, Yang Y, Denas G, Pengo V. Prevalence of a phosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta‐analysis. Thromb Res. 2022;214:106‐114. doi:10.1016/j.thromres.2022.04.021. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti‐prothrombin (aPT) and anti‐phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354‐364. doi:10.1160/TH13‐06‐0509. Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon‐Durey MA. Prevalence and significance of non‐conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971. doi:10.3389/fimmu.2018.02971. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine‐prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43(9):1982‐1993. doi:10.1002/1529‐0131(200009)43:9<1982::AID‐ANR9>3.0.CO;2‐2. Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE. Laboratory evaluation of anti‐phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at‐risk patient cohort. Clin Exp Immunol. 2015;180(2):218‐226. doi:10.1111/cei.12573. Cattini MG, Bison E, Pontara E, Cheng C, Denas G, Pengo V. Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti‐phosphatidyl‐serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost. 2020;18(5):1124‐1132. doi:10.1111/jth.14765. Pengo V, Del Ross T, Ruffatti A, et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res. 2018;12(172):172‐178. doi:10.1016/j.thromres.2018.11.003. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5(5):925‐930. doi:10.1111/j.1538‐7836.2007.02454.x. Tonello M, Bison E, Cattini MG, et al. Anti‐phosphatidyl‐serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? Clin Chem Lab Med. 2021;59(12):1950‐1953. doi:10.1515/cclm‐2021‐0692. Pengo V. Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: response from Pengo. J Thromb Haemost. 2020;18(11):3118‐3119. doi:10.1111/jth.15026. Tripodi A. Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2020;18(11):3117‐3118. doi:10.1111/jth.15056. Vandevelde A, Chayoua W, de Laat B, et al. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: communication from the ISTH SSC subcommittee on lupus anticoagulant/antiphospholipid antibodies. J Thromb Haemost. 2022;20(9):2136‐2150. doi:10.1111/jth.15785. |
| فهرسة مساهمة: | Keywords: LAC titer; antiphosphatidylserine/prothrombin; antiphospholipid syndrome; lupus anticoagulant; serial dilutions |
| المشرفين على المادة: | 0 (Lupus Coagulation Inhibitor) 9001-26-7 (Prothrombin) 0 (Immunoglobulin M) 0 (Phosphatidylserines) 0 (Immunoglobulin Isotypes) |
| تواريخ الأحداث: | Date Created: 20240221 Date Completed: 20240703 Latest Revision: 20240725 |
| رمز التحديث: | 20240726 |
| DOI: | 10.1111/ijlh.14251 |
| PMID: | 38380742 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1751-553X |
|---|---|
| DOI: | 10.1111/ijlh.14251 |